폐 약물전달 디바이스 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)
Pulmonary Drug Delivery Devices Market (Product Type: Dry Powder Inhalers, Metered Dose Inhalers, and Nebulizers; Application: Asthma, COPD, and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
상품코드:1402889
리서치사:Transparency Market Research
발행일:2023년 11월
페이지 정보:영문 170 Pages
라이선스 & 가격 (부가세 별도)
한글목차
폐 약물전달 디바이스 시장 - 보고서의 범위
TMR의 세계 폐 약물전달 디바이스 시장에 대한 보고서는 과거와 현재의 성장 동향과 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻을 수 있는 기회를 조사했습니다. 이 보고서는 2023년을 기준 연도 및 2031년을 예측 연도로 간주하여 2017년부터 2031년까지의 세계 폐 약물전달 디바이스 시장의 수익을 제공합니다. 이 보고서는 또한 2023년부터 2031년까지 세계 폐 약물전달 디바이스 시장의 복합 연간 성장률(CAGR%)을 제공합니다.
이 보고서는 광범위한 조사를 통해 작성되었습니다. KOL(Key Opinion Leader), 업계 리더 및 제조업체를 인터뷰하는 1차 조사 활동의 대부분을 분석가들이 수행했으며, 2차 조사에는 XX 시장을 이해하기 위해 주요 업체의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서 참조가 포함되었습니다.
시장 현황
2023년 시장 가치
372억 달러
2031년 시장 가치
550억 달러
CAGR
4.4%
이 보고서는 세계 폐 약물전달 디바이스 시장 경쟁 구도를 자세히 조사했습니다. 세계 폐 약물전달 디바이스 시장에서 활동하는 주요 기업을 파악할 수 있으며, 이들 각각은 다양한 속성 측면에서 프로파일링됩니다. 기업 프로파일, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 소개된 세계 폐 약물전달 디바이스 시장 기업의 속성입니다.
목차
제1장 주요 요약
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
시장 세분화
개요
시장 역학
세계 시장 분석과 예측, 2023-2031년
제5장 주요 인사이트
파이프라인 분석
세계 주요 국가의 질병 유병률과 이환율
COVID-19 팬데믹이 업계에 미치는 영향
제6장 시장 분석과 예측 : 제품 유형별
서론과 정의
주요 조사 결과/발전
시장 매출과 수량 예측 : 제품 유형별, 2023-2031
드라이 파우더 흡입기
정량 흡입기
네뷸라이저
시장 매력도 : 제품 유형별
제7장 시장 분석과 예측 : 용도별
서론과 정의
주요 조사 결과/발전
시장 매출과 수량 예측 : 용도별, 2023-2031
천식
COPD
낭포성 섬유증
기타
시장 매력도 : 용도별
제8장 세계 시장 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과/발전
시장 매출과 수량 예측 : 유통 채널별, 2023-2031
소매 약국
병원 약국
E-Commerce
시장 매력도 : 유통 채널별
제9장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출과 수량 예측 : 지역별, 2023-2031
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장 매력도 : 지역별
제10장 북미 시장 분석과 예측
제11장 유럽 시장 분석과 예측
제12장 아시아태평양 시장 분석과 예측
제13장 라틴아메리카 시장 분석과 예측
제14장 중동 및 아프리카 시장 분석과 예측
제15장 경쟁 구도
시장 기업--경쟁 매트릭스(기업 Tier 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
AstraZeneca Plc
Novartis AG
Boehringer Ingelheim GmbH
GlaxoSmithKline Plc
Merck &Co., Inc.
Teva Pharmaceutical Industries Ltd.
LSH
영문 목차
영문목차
Pulmonary Drug Delivery Devices Market - Scope of Report
TMR's report on the global pulmonary drug delivery devices market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global pulmonary drug delivery devices market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pulmonary drug delivery devices market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pulmonary drug delivery devices market.
Market Snapshot
Market Value in 2023
US$ 37.2 Bn
Market Value in 2031
US$ 55 Bn
CAGR
4.4%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pulmonary drug delivery devices market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pulmonary drug delivery devices market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pulmonary drug delivery devices market.
The report delves into the competitive landscape of the global pulmonary drug delivery devices market. Key players operating in the global pulmonary drug delivery devices market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pulmonary drug delivery devices market profiled in this report.
Key Questions Answered in Global pulmonary drug delivery devices Market Report:
What is the sales/revenue generated by pulmonary drug delivery devices across all regions during the forecast period?
What are the opportunities in the global pulmonary drug delivery devices market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Pulmonary Drug Delivery Devices Market - Research Objectives and Research Approach
The comprehensive report on the global pulmonary drug delivery devices market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global pulmonary drug delivery devices market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pulmonary drug delivery devices market.
Table of Contents
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pulmonary Drug Delivery Devices Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value & Volume Forecast, by Product Type, 2023-2031
6.3.1. Dry Powder Inhalers
6.3.2. Metered Dose Inhalers
6.3.3. Nebulizers
6.4. Market Attractiveness, by Product Type
7. Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Application
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value & Volume Forecast, by Application, 2023-2031
7.3.1. Asthma
7.3.2. COPD
7.3.3. Cystic Fibrosis
7.3.4. Others
7.4. Market Attractiveness, by Application
8. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Distribution Channel
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
8.3.1. Retail Pharmacies
8.3.2. Hospital Pharmacies
8.3.3. E-Commerce
8.4. Market Attractiveness, by Distribution Channel
9. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value & Volume Forecast, by Region, 2023-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Pulmonary Drug Delivery Devices Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value & Volume Forecast, by Product Type, 2023-2031
10.2.1. Dry Powder Inhalers
10.2.2. Metered Dose Inhalers
10.2.3. Nebulizers
10.3. Market Attractiveness, by Product Type
10.4. Market Value & Volume Forecast, by Application, 2023-2031
10.4.1. Asthma
10.4.2. COPD
10.4.3. Cystic Fibrosis
10.4.4. Others
10.5. Market Attractiveness, by Application
10.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
10.6.1. Retail Pharmacies
10.6.2. Hospital Pharmacies
10.6.3. E-Commerce
10.7. Market Attractiveness, by Distribution Channel
10.8. Market Value & Volume Forecast, by Country, 2023-2031
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Product Type
10.9.2. By Application
10.9.3. By Distribution Channel
10.9.4. By Country
11. Europe Pulmonary Drug Delivery Devices Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value & Volume Forecast, by Product Type, 2023-2031
11.2.1. Dry Powder Inhalers
11.2.2. Metered Dose Inhalers
11.2.3. Nebulizers
11.3. Market Attractiveness, by Product Type
11.4. Market Value & Volume Forecast, by Application, 2023-2031
11.4.1. Asthma
11.4.2. COPD
11.4.3. Cystic Fibrosis
11.4.4. Others
11.5. Market Attractiveness, by Application
11.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
11.6.1. Retail Pharmacies
11.6.2. Hospital Pharmacies
11.6.3. E-Commerce
11.7. Market Attractiveness, by Distribution Channel
11.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Market Attractiveness Analysis
11.9.1. By Product Type
11.9.2. By Application
11.9.3. By Distribution Channel
11.9.4. By Country/Sub-region
12. Asia Pacific Pulmonary Drug Delivery Devices Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value & Volume Forecast, by Product Type, 2023-2031
12.2.1. Dry Powder Inhalers
12.2.2. Metered Dose Inhalers
12.2.3. Nebulizers
12.3. Market Attractiveness, by Product Type
12.4. Market Value & Volume Forecast, by Application, 2023-2031
12.4.1. Asthma
12.4.2. COPD
12.4.3. Cystic Fibrosis
12.4.4. Others
12.5. Market Attractiveness, by Application
12.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
12.6.1. Retail Pharmacies
12.6.2. Hospital Pharmacies
12.6.3. E-Commerce
12.7. Market Attractiveness, by Distribution Channel
12.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Product Type
12.9.2. By Application
12.9.3. By Distribution Channel
12.9.4. By Country/Sub-region
13. Latin America Pulmonary Drug Delivery Devices Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value & Volume Forecast, by Product Type, 2023-2031
13.2.1. Dry Powder Inhalers
13.2.2. Metered Dose Inhalers
13.2.3. Nebulizers
13.3. Market Attractiveness, by Product Type
13.4. Market Value & Volume Forecast, by Application, 2023-2031
13.4.1. Asthma
13.4.2. COPD
13.4.3. Cystic Fibrosis
13.4.4. Others
13.5. Market Attractiveness, by Application
13.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
13.6.1. Retail Pharmacies
13.6.2. Hospital Pharmacies
13.6.3. E-Commerce
13.7. Market Attractiveness, by Distribution Channel
13.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Product Type
13.9.2. By Application
13.9.3. By Distribution Channel
13.9.4. By Country/Sub-region
14. Middle East & Africa Pulmonary Drug Delivery Devices Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value & Volume Forecast, by Product Type, 2023-2031
14.2.1. Dry Powder Inhalers
14.2.2. Metered Dose Inhalers
14.2.3. Nebulizers
14.3. Market Attractiveness, by Product Type
14.4. Market Value & Volume Forecast, by Application, 2023-2031
14.4.1. Asthma
14.4.2. COPD
14.4.3. Cystic Fibrosis
14.4.4. Others
14.5. Market Attractiveness, by Application
14.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
14.6.1. Retail Pharmacies
14.6.2. Hospital Pharmacies
14.6.3. E-Commerce
14.7. Market Attractiveness, by Distribution Channel
14.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Product Type
14.9.2. By Application
14.9.3. By Distribution Channel
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AstraZeneca Plc
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Type Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Novartis AG
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Type Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Boehringer Ingelheim GmbH
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Type Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. GlaxoSmithKline Plc
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Type Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Merck & Co., Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Type Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Teva Pharmaceutical Industries Ltd.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
